Identification of small molecule inhibitors of Trypanosoma PEX15--PEX6 interaction

Hohnen, L.; Tippler, B. G.; Tiris, F.; Erdmann, R.; Kalel, V. C.

doi:10.1101/2025.10.03.680009

Home/Archive/bioRxiv

bioRxiv · 10.1101/2025.10.03.680009

Identification of small molecule inhibitors of Trypanosoma PEX15--PEX6 interaction

Hohnen, L.·Tippler, B. G.·Tiris, F.·Erdmann, R.·Kalel, V. C.

View original source ↗Export metadata ↓

Abstract

Trypanosomatid parasites that cause life threatening tropical diseases harbor specialized essential organelles, called glycosomes. Like other peroxisome-related organelles, the biogenesis of glycosomes is mediated by proteins known as peroxins (PEX). A cascade of PEX protein-protein interactions (PPIs) is essential for glycosome function and parasite survival. Accordingly, small molecule inhibitors of PEX proteins that disrupt glycosomal matrix or membrane protein import have been reported as potential therapies for trypanosomiasis. We recently identified the long sought-after Trypanosoma PEX15 (TbPEX15), which anchors the PEX1-PEX6 complex to the glycosomal membrane for recycling of the receptor PEX5. Defects in this process cause PEX5 degradation, mislocalization of glycosomal matrix proteins and parasite death. In this study, we targeted the interaction between TbPEX6 and TbPEX15. Recombinant TbPEX6 and TbPEX15 were purified, and their interaction was confirmed by in vitro pull-down assays and size exclusion chromatography. Furthermore, we established an AlphaScreen-based method to identify small molecule inhibitors of this PPI. Screening of a drug-repurposing library identified two inhibitors with trypanocidal activity against T. brucei in vitro and the amastigote stage of T. cruzi. Given its essentiality and low sequence similarity to its human homolog, parasite PEX15 and its interaction with PEX6 represent promising targets for the development of new therapies against trypanosomatid infections.

Explore related subjects

microbiology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Hohnen, L., Tippler, B. G., Tiris, F., Erdmann, R., Kalel, V. C.. 2025-10-04. Identification of small molecule inhibitors of Trypanosoma PEX15--PEX6 interaction. https://doi.org/10.1101/2025.10.03.680009

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

pTRIP, a novel integration plasmid for Listeria monocytogenes

In the past decades, several tools to genetically modify the human pathogen Listeria monocytogenes were developed. Here, we constructed a new integrative plasmid system for L. monocytogenes named pTRIP, for treB insertion plasmid. pTRIP is a vector which stably integrates into the treB locus of the wild type EGD-e. This locus encodes the sole trehalose-specific EIIB and EIIC component of a phosphotransferase system. Successful integration leads to the disruption of treB and thus, to an inability of the resulting L. monocytogenes strains to grow on trehalose as sole carbon source. Due to integration through double homologous recombination, it is the first integrative system which does not require antibiotic selection pressure. To assess functionality of the pTRIP system, prfA and its native promoter region were integrated into the treB locus of a {Delta}prfA strain. Complementation was confirmed in 78% of the isolated clones, indicating successful integration of prfA into the treB locus. We further constructed derivatives of pTRIP harboring the constitutive Pp60 (pTRIP1) and the inducible Prha (pTRIP2) promoter to further expand application possibilities. Microscopic analyses confirmed the functionality of both promoter constructs and showed dose-dependent induction for Prha. pTRIP is an efficient tool for stable gene expression as well as functional studies and expands genetic modification possibilities for L. monocytogenes.

microbiology↗

bioRxiv2026

A rational design strategy and validation for protease-resistant fusion-inhibitor antiviral peptides

Peptide-based fusion inhibitors are promising pharmaceuticals in the fight against enveloped viruses relying on membrane fusion for host infection. However, peptide therapeutic applications have long been hindered by their poor stability in vivo. Here, we discovered that peptide inhibitors with the wildtype sequence of the heptad repeat 2 (HR2) domain of the SARS-CoV-2 spike protein are efficiently cleaved by Transmembrane Protease, Serine 2 (TMPRSS2), a key protease involved in the SARS-CoV-2 virus-cell fusion pathway. We then identified the corresponding cleavage sites and designed three protease-resistant peptides using ranking based on deep mutational scanning and natural occurrence. The three candidates all exhibit inhibitory activity in a cell-cell fusion assay. A high-resolution cryo-EM structure of the top candidate, HR2-NHN, bound to its HR1 target reveals the molecular basis for its potent activity. The top candidate of the cell-based screening assay significantly improved efficacy relative to the wildtype peptide when administered 12 h before infection in both an authentic virus-cell infection assay and a mouse assay. More broadly, our results suggest that the design strategies for protease-resistant peptides could be applied to a broad spectrum of other enveloped viruses and pave the way for the development of safe, prophylactic antivirals that can be administered before exposure.

microbiology↗

bioRxiv2026

Host soluble inositol phosphate signaling promotes coronavirus replication

Coronaviruses rely extensively on host pathways for replication, making host-directed therapies an attractive strategy for broad-spectrum antivirals with reduced risk of viral resistance. Here we identify the host soluble inositol phosphate pathway as a previously unrecognized dependency for coronavirus infection. Genetic or pharmacologic inhibition of several kinases in this pathway markedly suppresses replication of both alpha- and betacoronaviruses, while increasing pathway activity promotes viral replication. We developed UNC7844, a potent multi-target inhibitor of these kinases, which reduces coronavirus replication by more than four orders of magnitude in cultured cells and suppresses coronavirus infection in mice. Mechanistically, UNC7844 suppresses inositol (pyro)phosphates production, disrupts phosphoinositide homeostasis, and impairs late endosomal dynamics, blocking early post-entry steps required for viral genome release and replication. Together, our findings establish the soluble inositol (pyro)phosphate pathway as an important regulator of coronavirus infection and highlight its inhibition as a promising host-directed antiviral strategy.

microbiology↗